Boston Family Office LLC Reduces Stock Position in IQVIA Holdings Inc. $IQV

Boston Family Office LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 7.6% in the 2nd quarter, Holdings Channel reports. The firm owned 124,007 shares of the medical research company’s stock after selling 10,147 shares during the quarter. IQVIA accounts for approximately 1.3% of Boston Family Office LLC’s portfolio, making the stock its 25th largest position. Boston Family Office LLC’s holdings in IQVIA were worth $19,542,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Verdence Capital Advisors LLC bought a new position in IQVIA in the second quarter valued at $3,612,000. Act Two Investors LLC purchased a new position in shares of IQVIA in the 2nd quarter worth about $26,528,000. Patton Fund Management Inc. purchased a new position in shares of IQVIA in the 2nd quarter worth about $231,000. Shell Asset Management Co. raised its holdings in shares of IQVIA by 78.7% during the 2nd quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company’s stock valued at $1,459,000 after buying an additional 4,077 shares in the last quarter. Finally, Heritage Investors Management Corp lifted its position in IQVIA by 10.5% in the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock worth $16,500,000 after buying an additional 9,909 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Stock Down 1.8%

Shares of NYSE:IQV opened at $227.63 on Monday. The stock’s 50-day moving average is $210.07 and its 200 day moving average is $184.07. The company has a market cap of $38.77 billion, a PE ratio of 31.23, a P/E/G ratio of 2.58 and a beta of 1.34. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $234.29.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IQV shares. Evercore ISI increased their price target on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Citigroup increased their target price on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Friday. Finally, TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and boosted their target price for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $240.61.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.